Erasca Raises $225M in Upsized Public Offering of Common Stock
ByAinvest
Wednesday, Jan 21, 2026 8:57 pm ET1min read
ERAS--
Erasca, a clinical-stage precision oncology company, has announced the pricing of an upsized public offering of 22.5 million shares of common stock at $10.00 per share, raising $225 million in gross proceeds. The company plans to use the funds to fund research and development of its product candidates and for general corporate purposes. The offering is expected to close on January 23, 2026.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet